Last reviewed · How we verify
Vyepti (EPTINEZUMAB)
Vyepti works by blocking the action of calcitonin gene-related peptide 1, a molecule involved in migraine pain.
At a glance
| Generic name | EPTINEZUMAB |
|---|---|
| Sponsor | Lundbeck Seattle BioPharmaceuticals, Inc. |
| Drug class | Calcitonin Gene-related Peptide Antagonist [EPC] |
| Target | Calcitonin gene-related peptide 1 |
| Modality | Monoclonal antibody |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2020 |
| Annual revenue | 300 |
Mechanism of action
Eptinezumab-jjmr is humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Approved indications
- Migraine
- Prevention of migraine attacks
Common side effects
- Nasopharyngitis
- Hypersensitivity reactions
- Anaphylaxis
- Anti-eptinezumab-jjmr antibody development
- Anti-eptinezumab-jjmr neutralizing antibodies
Key clinical trials
- A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PHASE3)
- A Study of Eptinezumab in Pediatric Participants With Episodic Migraine (PHASE3)
- A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine (PHASE3)
- A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications (PHASE4)
- A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache (PHASE4)
- The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)
- China HeadAche DIsorders RegiStry
- Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vyepti CI brief — competitive landscape report
- Vyepti updates RSS · CI watch RSS
- Lundbeck Seattle BioPharmaceuticals, Inc. portfolio CI